Who Is Neil Buddy Shah, the Chair of Anthropic's Trust?

Dr. Neil "Buddy" Shah chairs Anthropic's Long-Term Benefit Trust (LTBT) and runs the Clinton Health Access Initiative (CHAI). He has chaired the LTBT since June 2023 and served as CEO of CHAI since June 2022.

At Layer3Labs, we build AI automations for business workflows, and a model provider's board structure is one of the things a team checks before building on that provider.

Anthropic's Form S-1, filed with the Securities and Exchange Commission (SEC) on October 26, 2026, says Shah will also serve as an initial manager of the Anthropic Public Benefit Fund. He is paid $400,000 a year as a Trustee plus $25,000 a year as Chair.

Who Neil Buddy Shah Is

Dr. Neil "Buddy" Shah is the Chief Executive Officer of the Clinton Health Access Initiative. He also chairs the Long-Term Benefit Trust. The Trust generally elects and removes the four Class T directors, who will form a majority of Anthropic's board. Anthropic is organized as a Public Benefit Corporation (PBC) with a dedicated Company Purpose: the responsible development and maintenance of advanced artificial intelligence (AI) for the long-term benefit of humanity. Shah was appointed as an inaugural trustee and chair of the Long-Term Benefit Trust when Anthropic announced the body on September 19, 2023, having formally served in the role since June 2023.

Anthropic's SEC filing discloses that Shah receives annual cash compensation of $400,000 for serving as an LTBT trustee, plus an additional $25,000 per year for serving as chair. The filing notes that he was selected because of his expertise in global health, impact measurement, and social enterprise, as well as his background evaluating the long-term societal effects of large-scale programs.

Anthropic's S-1 notes that Shah will also serve as one of the four initial managers of the Anthropic Public Benefit Fund, alongside chief executive officer Dario Amodei, president Daniela Amodei, and Jack Clark. The filing does not state Shah's age or net worth.

Career and Background in Global Health and Economics

According to Anthropic's S-1, Shah holds an A.B. in Economics from Harvard University. He also earned an M.D. with an emphasis in global health policy from the Albert Einstein College of Medicine, and an M.P.A. in International Development from the Harvard Kennedy School of Government.

Shah co-founded and served as Chief Executive Officer of IDinsight, a global advisory, data analytics, and research organization.

Following his work at IDinsight, Shah became Managing Director of GiveWell, a nonprofit organization focused on directing charitable capital toward cost-effective global health and development programs. In June 2022, he became CEO of the Clinton Health Access Initiative, a global health organization focused on improving access to health services in low- and middle-income countries.

Role and Authority at the Long-Term Benefit Trust

Anthropic's Long-Term Benefit Trust is a common law noncharitable purpose trust under Delaware law. Its governing document is the Long-Term Benefit Trust Amended and Restated Trust Agreement. The LTBT is intended to balance three distinct priorities: the pecuniary interests of stockholders, the best interests of those materially affected by Anthropic's conduct, and the public benefit Company Purpose. The LTBT works through Class T common stock. It is the sole holder, and the stock has no economic rights.

According to the October 2026 Anthropic Form S-1 registration statement, Anthropic's board of directors will have seven authorized seats after its initial public offering (IPO). Through Class T common stock, the LTBT generally holds the authority to elect and remove four Class T directors, which constitutes a voting majority of the board. The filing names the initial Class T directors: Reed Hastings, Vas Narasimhan and Christopher Liddell. One seat is vacant. Christopher Liddell will serve as the Specified Class T Director, subject to special nomination and removal rules involving Anthropic's nominating and governance committee (NGC) and Class E stockholders. Class A and Class F common stock, voting together, elect the remaining three directors, who will initially be Dario Amodei, Daniela Amodei, and Yasmin Razavi.

Neither the LTBT nor the Trustees have decision-making authority in the day-to-day management or strategy setting of Anthropic. The S-1 says the board of directors makes decisions about Anthropic's business and affairs. The LTBT's job is to select directors capable of balancing public benefit with shareholder interests. Under Delaware law, fundamental corporate transactions such as mergers, consolidations, or the sale of all or substantially all assets require board approval, a majority of whom are elected by the LTBT.

Trustee Roster and Governance Mechanics

The LTBT has five authorized Trustees. One seat was vacant as of the S-1 filing date. Terms are annual, with no limit on the number of terms. When Anthropic introduced the trust on Anthropic's website in September 2023, the initial trustees alongside Shah were Jason Matheny, Kanika Bahl, Paul Christiano, and Zach Robinson. Matheny departed in December 2023, Christiano left in April 2024, and Bahl and Robinson stepped down in January 2026.

As disclosed in the S-1, three other Trustees serve with Shah. Richard Fontaine, CEO of the Center for a New American Security (CNAS), joined in April 2025. Dr. Ben S. Bernanke, former Chairman of the Federal Reserve System, joined in June 2026. Dr. Christopher Stubbs joined in October 2026. Trustees appoint Trustees by majority vote of those in office. A majority of the authorized Trustees can remove a Trustee. So can the Delaware Court of Chancery, for disqualifying conduct.

On April 14, 2026, Anthropic announced that the LTBT appointed Vas Narasimhan, CEO of Novartis, to the board. Anthropic said Trust-appointed directors then made up a majority of the board. In that announcement, Shah stated: "We're excited for what he'll bring to the table."

Public Benefit Fund and Financial Independence Protections

The S-1 says the LTBT's arrangements are designed to minimize the Trustees' exposure to Anthropic's financial performance. Each Trustee receives $400,000 a year in cash. Shah receives $25,000 more as Chair. The S-1 says Trustee compensation will not vary with or be conditioned upon Anthropic's profits or any action or inaction of Anthropic. The policies of the LTBT prohibit a Trustee from directly purchasing or holding any Anthropic securities.

Anthropic also created the Anthropic Public Benefit Fund, a wholly owned subsidiary dedicated to advancing the Company Purpose. According to the S-1, Anthropic contributed 846,840,960 shares of Class N common stock to this fund. That is 5% of its fully diluted shares as of June 30, 2026, assuming full conversion of the convertible notes described in the S-1. The fund's four initial managers are Shah, Dario Amodei, Daniela Amodei and Jack Clark. The board determines allocations until it approves a specific governance structure, after which decision-making is expected to transition to the designated managers.

Anthropic accounts for the LTBT as a consolidated variable interest entity (VIE) on its balance sheet. Financial disclosures in the S-1 indicate that Anthropic funded the LTBT with $2,716,750 in 2023, $0 in 2024, $906,089 in 2025, and $8,425,213 during the first nine months of 2026. In August 2026, Anthropic also made a $450,000 charitable donation to CNAS, where fellow trustee Richard Fontaine serves as CEO.

What Trust Governance Means for Enterprise Claude Users

The S-1 says neither the LTBT nor the Trustees have decision-making authority in the day-to-day management or strategy setting of Anthropic. So Shah's role matters to a vendor decision only as a board-control fact. For detailed pricing metrics across model tiers, teams can consult our Claude API pricing guide.

Anthropic cautions in its S-1 risk factors that "the LTBT may have interests that differ from yours, and it may exercise its power in a way with which you disagree or in a way that may be adverse to your interests." Class F stock held by the Founder LLC carries 50.1% of the total voting power on matters submitted to stockholders generally, which makes Anthropic a controlled company under listing rules. The LTBT generally elects and removes the four Class T directors, and one of those seats is vacant.

If you are deciding whether to commit enterprise workflows to Claude, start with the Anthropic S-1 vendor risk guide. Re-read the S-1 governance and risk-factor sections after the offering prices. Three things could change the balance of control. The Trust or the Class T terms could be amended (the S-1 sets approval thresholds that depend on whether the Trustees vote in favor). The vacant Trustee and Class T director seats could be filled. The final IPO terms could change.